(Q36499578)

14 August 2017

1 reference

title

The proteasome: a novel target for anticancer therapy (English)

1 reference

14 August 2017

Montagut C

1

1 reference

PubMed ID

16760005

14 August 2017

Rovira A

series ordinal

2

1 reference

PubMed ID

16760005

14 August 2017

Albanell J

series ordinal

3

1 reference

14 August 2017

1 May 2006

1 reference

Clinical and Translational Oncology

14 August 2017

1 reference

14 August 2017

8

1 reference

14 August 2017

313-317

1 reference

14 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-006-0176-8

14 August 2017

0 references

cites work

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-006-0176-8

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma

21 January 2018

1 reference

12 December 2020

Lactacystin inhibits cathepsin A activity in melanoma cell lines

1 reference

12 December 2020

Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

1 reference

12 December 2020

A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3.

1 reference

12 December 2020

p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.

1 reference

12 December 2020

Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome).

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

12 December 2020

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

1 reference

12 December 2020

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

1 reference

12 December 2020

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor

1 reference

12 December 2020

Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse

1 reference

12 December 2020

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

1 reference

12 December 2020

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

12 December 2020

The proteasome, a novel protease regulated by multiple mechanisms

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

12 December 2020

Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma

1 reference

12 December 2020

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

1 reference

12 December 2020

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

12 December 2020

The ubiquitin-proteasome pathway: on protein death and cell life

1 reference

12 December 2020

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

1 reference

12 December 2020

Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C.

1 reference

12 December 2020

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma

1 reference

12 December 2020

Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment

1 reference

12 December 2020

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

1 reference

12 December 2020

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

12 December 2020

Proteasome inhibitors as new anticancer drugs

1 reference

12 December 2020

NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis

1 reference

12 December 2020

The proteasome: a macromolecular assembly designed for controlled proteolysis

1 reference

12 December 2020

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

12 December 2020

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

12 December 2020

Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

1 reference

12 December 2020

Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes

1 reference

12 December 2020

The proteasome is involved in angiogenesis

1 reference

12 December 2020

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

In vivo ubiquitination and proteasome-mediated degradation of p53(1)

1 reference

12 December 2020

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

12 December 2020

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

12 December 2020

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

1 reference

12 December 2020

Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells

1 reference

12 December 2020

Proteasome inhibitors and antigen presentation

1 reference

12 December 2020

Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells

1 reference

12 December 2020

Recognition of the polyubiquitin proteolytic signal

1 reference

12 December 2020

Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Mechanisms underlying ubiquitination

1 reference

12 December 2020

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin

1 reference

12 December 2020

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

12 December 2020

cDNA cloning and sequencing of component C9 of proteasomes from rat hepatoma cells

1 reference

12 December 2020

NF-kappaB in cancer: from innocent bystander to major culprit

1 reference

12 December 2020

Subcellular localization of proteasomes and their regulatory complexes in mammalian cells.

1 reference

12 December 2020

Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.

1 reference

12 December 2020

Proteasome inhibitors: from research tools to drug candidates

1 reference

12 December 2020

Eponemycin exerts its antitumor effect through the inhibition of proteasome function.

1 reference

12 December 2020

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67

1 reference

12 December 2020

Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB

1 reference

12 December 2020

Structure and assembly of the 20S proteasome

1 reference

12 December 2020

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

1 reference

12 December 2020

10.1007/S12094-006-0176-8

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16760005